Aduro Biotech to Present at LEERINK Partners Roundtable Series
September 22 2016 - 8:00AM
Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T.
Isaacs, chairman, president and chief executive officer of Aduro,
will present at the LEERINK Partners Roundtable Series: Rare
Disease & Immuno-Oncology in New York, NY on Thursday,
September 29, 2016, at 8:00 am Eastern Time.
To access the live webcast and subsequent
archived recording of this and the company’s other presentations,
please visit Aduro's website at www.aduro.com.
About Aduro Aduro Biotech, Inc.
is an immunotherapy company focused on the discovery, development
and commercialization of therapies that transform the treatment of
challenging diseases. Aduro's technology platforms, which are
designed to harness the body's natural immune system, are being
investigated in cancer indications and have the potential to expand
into autoimmune and infectious diseases. Aduro's LADD technology
platform is based on proprietary attenuated strains of Listeria
that have been engineered to express tumor-associated antigens to
induce specific and targeted immune responses. This platform is
being developed as a treatment for multiple indications, including
pancreatic, ovarian, lung and prostate cancers, mesothelioma and
glioblastoma. Aduro's STING Pathway Activator platform is designed
to activate the intracellular STING receptor, resulting in a potent
tumor-specific immune response. ADU-S100 is the first STING Pathway
Activator compound to enter the clinic and is currently being
evaluated in a Phase 1 study in patients with cutaneously
accessible metastatic solid tumors or lymphomas. Aduro’s B-select
monoclonal antibody platform includes a number of immune modulating
assets in research and preclinical development. Aduro is
collaborating with leading global pharmaceutical companies to
expand its products and technology platforms. For more information,
please visit www.aduro.com.
Contact:
Alexandra Santos
Sr. Director, Corporate Affairs
510 809 9231
Media Contact:
Angela Bitting
925 202 6211
press@aduro.com
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Apr 2023 to Apr 2024